Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, Sültmann H.

Sci Rep. 2016 Sep 19;6:33505. doi: 10.1038/srep33505.

2.

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.

Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, Muley T, Thomas M, Sültmann H.

PLoS One. 2016 Aug 16;11(8):e0161012. doi: 10.1371/journal.pone.0161012. eCollection 2016.

3.

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.

Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S.

Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845.

4.

Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.

Praveen P, Hülsmann H, Sültmann H, Kuner R, Fröhlich H.

Sci Rep. 2016 Jun 9;6:27514. doi: 10.1038/srep27514.

5.

Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment.

Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sültmann H, Altevogt P, Umansky V, Momma S.

Oncoimmunology. 2015 Mar 19;4(6):e1008371. eCollection 2015 Jun.

6.

Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells.

Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS Pathog. 2015 Mar 11;11(3):e1004712. doi: 10.1371/journal.ppat.1004712. eCollection 2015 Mar.

7.

Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains.

Pandey V, Sultan M, Kashofer K, Ralser M, Amstislavskiy V, Starmann J, Osprian I, Grimm C, Hache H, Yaspo ML, Sültmann H, Trauner M, Denk H, Zatloukal K, Lehrach H, Wierling C.

PLoS One. 2014 Oct 27;9(10):e111006. doi: 10.1371/journal.pone.0111006. eCollection 2014.

8.

Novel RNA markers in prostate cancer: functional considerations and clinical translation.

Pickl JM, Heckmann D, Ratz L, Klauck SM, Sültmann H.

Biomed Res Int. 2014;2014:765207. doi: 10.1155/2014/765207. Epub 2014 Aug 28. Review.

9.

Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation.

Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S.

PLoS Biol. 2014 Jun 3;12(6):e1001874. doi: 10.1371/journal.pbio.1001874. eCollection 2014 Jun.

10.

The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.

Hussong M, Börno ST, Kerick M, Wunderlich A, Franz A, Sültmann H, Timmermann B, Lehrach H, Hirsch-Kauffmann M, Schweiger MR.

Cell Death Dis. 2014 Apr 24;5:e1195. doi: 10.1038/cddis.2014.157.

11.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

12.

ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.

Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Börno ST, Fälth M, Kuner R, Lehrach H, Schweiger MR, Sültmann H.

PLoS One. 2013;8(3):e59976. doi: 10.1371/journal.pone.0059976. Epub 2013 Mar 29.

13.

A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.

Hellwinkel OJ, Sellier C, Sylvester YM, Brase JC, Isbarn H, Erbersdobler A, Steuber T, Sültmann H, Schlomm T, Wagner C.

Int J Mol Sci. 2013 Mar 4;14(3):5239-49. doi: 10.3390/ijms14035239.

14.

Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.

Massoner P, Kugler KG, Unterberger K, Kuner R, Mueller LA, Fälth M, Schäfer G, Seifarth C, Ecker S, Verdorfer I, Graber A, Sültmann H, Klocker H.

PLoS One. 2013;8(2):e55207. doi: 10.1371/journal.pone.0055207. Epub 2013 Feb 4.

15.

Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis.

Starmann J, Fälth M, Spindelböck W, Lanz KL, Lackner C, Zatloukal K, Trauner M, Sültmann H.

PLoS One. 2012;7(10):e46584. doi: 10.1371/journal.pone.0046584. Epub 2012 Oct 10.

16.

Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer.

Gade S, Porzelius C, Fälth M, Brase JC, Wuttig D, Kuner R, Binder H, Sültmann H, Beissbarth T.

BMC Bioinformatics. 2011 Dec 21;12:488. doi: 10.1186/1471-2105-12-488.

17.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H.

BMC Cancer. 2011 Dec 5;11:507. doi: 10.1186/1471-2407-11-507.

18.

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.

Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf TH, Balabanov S.

Mol Cancer. 2011 Oct 14;10:129. doi: 10.1186/1476-4598-10-129.

19.

Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity.

Kerick M, Isau M, Timmermann B, Sültmann H, Herwig R, Krobitsch S, Schaefer G, Verdorfer I, Bartsch G, Klocker H, Lehrach H, Schweiger MR.

BMC Med Genomics. 2011 Sep 29;4:68. doi: 10.1186/1755-8794-4-68.

20.

EZH2 depletion blocks the proliferation of colon cancer cells.

Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS One. 2011;6(7):e21651. doi: 10.1371/journal.pone.0021651. Epub 2011 Jul 13.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk